Enanta Pharmaceuticals, Inc. — Form 10-Q Summary
Reporting period: Fiscal third quarter and nine months ended June 30, 2023. Amounts below are in U.S. dollars; financial statement figures are unaudited. Enanta is a biotechnology company developing small-molecule therapies, primarily for viral infections. Its principal revenue source is royalties from AbbVie’s MAVYRET/MAVIRET hepatitis C treatment.
Financial performance
| Metric | Three months ended June 30, 2023 | Three months ended June 30, 2022 | Nine months ended June 30, 2023 | Nine months ended June 30, 2022 |
|---|---|---|---|---|
| Total revenue | $18.9 million | $19.5 million | $60.3 million | $65.8 million |
| Net loss | $39.1 million | $31.7 million | $105.7 million | $95.4 million |
| Net loss per share, diluted | $1.86 | $1.53 | $5.05 | $4.64 |
| Research and development expense | $43.0 million | $39.1 million | $127.4 million | $129.7 million |
| General and administrative expense | $12.6 million | $12.9 million | $39.1 million | $32.9 million |
- Quarterly operating loss was $36.7 million, compared with $32.5 million a year earlier. Nine-month operating loss was $106.2 million versus $96.8 million.
- Nine-month royalty revenue declined $6.6 million, attributed to lower AbbVie-reported HCV sales. A $1.0 million license payment for an antibacterial compound partly offset the decline.
- At June 30, cash, cash equivalents and marketable securities totaled $392.5 million. Total assets were $495.2 million, total liabilities $257.4 million, and stockholders’ equity $237.8 million. Accumulated deficit was $178.9 million.
- Operating cash use was $81.6 million for the nine months, versus $69.2 million in the prior-year period. Investing activities used $65.4 million; financing activities provided $198.1 million, principally from the royalty transaction. Cash, cash equivalents and restricted cash increased $51.2 million.
- The filing records no conventional borrowing balance, but includes a $201.7 million liability from the sale of future royalties, of which $36.7 million is current. Cash interest and investment income rose to $6.7 million for the nine months; the royalty liability generated $2.0 million of non-cash interest expense.
Material changes and unusual items
- In April 2023, Enanta received $200 million from an OMERS affiliate in exchange for 54.5% of MAVYRET/MAVIRET royalty payments after June 30, 2023 through June 30, 2032, subject to aggregate payments capped at 1.42 times the purchase price. Enanta accounts for the proceeds as a liability and continues to report 100% of royalties as revenue; payments to OMERS reduce the liability.
- Quarterly R&D expense increased $3.9 million, primarily from virology clinical trial costs and headcount. For the nine months, R&D declined $2.4 million as the substantial wind-down of the non-viral NASH program more than offset higher virology and other discovery costs.
- Nine-month G&A expense increased $6.2 million, including higher stock-based compensation and legal fees for the Pfizer patent suit. The $4.2 million nine-month tax expense was primarily related to the taxable OMERS payment; the comparable 2022 period included a $0.4 million tax benefit.
Outlook, programs and risks
- Management expects existing financial resources and continuing HCV royalties to fund operating and capital requirements into the second half of fiscal 2027. The filing cautions that this estimate depends on assumptions and actual cash needs or royalty receipts may differ. A separate financial-statement disclosure states resources are sufficient for at least 12 months from issuance.
- Enanta expects operating losses to continue for the foreseeable future. It expects external R&D expenses generally to decrease over the next 12 months because it does not plan to run an EDP-235 Phase 3 trial on its own; it expects G&A to increase in support of operations and the Pfizer litigation.
- RSV candidate EDP-938 was in three Phase 2 studies; management expected one or more to complete enrollment during the coming Northern Hemisphere RSV season and data in fiscal 2024, subject to a return to a more normal RSV season. EDP-323 reported positive Phase 1 topline results, with a Phase 2 challenge study targeted for the fourth quarter of 2023.
- EDP-235 met its Phase 2 primary endpoint and showed dose-dependent symptom improvement, with statistical significance in certain analyses. Enanta said it would pursue a partner for Phase 3 development and continue regulatory discussions. The filing reports no effect on nasal virologic endpoints in the overall study population.
- Management expected selection of a dual hMPV/RSV clinical candidate in the fourth quarter of 2023. The HBV candidate EDP-514 had completed Phase 1b studies; Enanta described a combination-treatment approach as its development goal.
- Enanta is pursuing a patent-infringement suit against Pfizer concerning Paxlovid and seeking compensation. Legal expenses are recorded as incurred; the filing does not state a clear estimate of potential recovery or litigation outcome. It reports no other current litigation and no material changes to previously disclosed risk factors.
Key investor verification points
- Track AbbVie’s MAVYRET/MAVIRET sales, royalty trends and Enanta’s retained royalty share after the OMERS transaction, along with the liability’s estimated accretion and payment schedule.
- Assess cash use against management’s runway estimate, including clinical-trial spending, capital expenditures and the timing of future HCV royalties.
- Verify subsequent clinical and regulatory updates for EDP-938, EDP-323, EDP-235, the hMPV/RSV program and EDP-514; timelines and outcomes remain uncertain.
- Monitor whether Enanta secures a development partner for EDP-235 and the financial or dilution consequences of any future financing or collaboration.
- Follow the Pfizer patent litigation and related legal costs; the filing provides no clear outcome or recovery value.